Dice Therapeutics, Inc., A Wholly Owned Subsidiary Of Eli Lilly And

At DICE, we are expecting more out of medicine. We design and develop innovative oral medicines against biologically validated targets in immunology for the treatment of chronic autoimmune and inflammatory diseases. Through combining innovative chemistry with well-validated biology, our goal is to make medicines more accessible and unlock the potential of oral medicines. Our team is led by an exceptional group of scientists, R&D executives and company builders with demonstrated track records of progressing programs from discovery through regulatory approval and commercialization. Together, we’re building a team that has a passion for innovation and extensive experience in small molecule drug discovery and development.